Background Smooth muscle cell proliferation and extracellular matrix accumulation are the principal mechanisms leading to vascular restenosis. We have previously demonstrated the growth-inhibitory effect of antisense oligomers targeting the c-myc proto-oncogene in human smooth muscle cells. The goal of this study was to investigate whether c-myc antisense oligomers reduce neointimal formation in balloon-denuded porcine coronary arteries.
Methods and Results First, type I collagen synthesis, which reflects synthetic function, was markedly reduced following c-myc antisense oligomers in porcine vascular smooth muscle cells independent of the growth inhibition. These effects in vitro provided the rationale for assessing c-myc antisense oligomers in the prevention of neointima in vivo. Second, the efficiency of single transcatheter delivery of oligomers into denuded porcine coronary arteries was determined. Despite rapid plasma clearance following local delivery, oligomers persisted at the site of injection for at least 3 days, exceeding by severalfold their concentration in peripheral organs. Third, morphometric analyses were carried out in balloon-denuded coronary arteries at 1 month after transcatheter c-myc an-V urascular smooth muscle cells (VSMCs) are Local transcatheter administration as an alternative for ODN transfer to the site of angioplasty is more practical, but it is currently limited by unproven efficiency as well as by rapidly developing myocardial ischemia if prolonged application is required. Therefore, the paucity of studies using a clinically applicable protocol to deliver antisense ODNs following coronary denudation requires the evaluation of this novel approach with an endoluminal route of administration in the coronary vasculature.
The present study has attempted to address the above unresolved issues using antisense ODNs directed against the c-myc proto-oncogene because of its involvement in the regulation of VSMC proliferation.10"'1 Ac- 24 hours afterward, and the cell number was counted. The samples were digested with pepsin (1 mg/mL) in 0.5 mol/L acetic acid overnight at 4°C. They were then lyophilized and resuspended in a buffer containing 1% SDS and 5% 2-mercaptoethanol. After being boiling for 5 minutes, the samples were electrophoresed in 7.5% (wt/vol) premade SDS polyacrylamide gels (BioRad). The fractionated proteins were then electrotransferred onto PolyScreen PVDF membranes (DuPont NEN) in transfer buffer containing 0.192 mol/L glycine, 25 mmol/L Trizma base, 0.01% SDS, and 20% methanol. The blots were then blocked in 5% nonfat milk in PBS and sequentially incubated with biotin-labeled anti-human type I collagen antibodies, which react with triple helical domain of the human type I collagen (Southern Biotechnology Associates, Inc), streptavidin-alkaline phosphate (Boehringer Mannheim), and chemiluminescence reagent (DuPont NEN) as described by the manufacturers. The membranes were exposed to Kodak X-Omat film and quantified by laser densitometry. Densitometric values were normalized by cell number, and the percent inhibition of collagen was calculated against control samples without the addition of ODNs.
Animal Preparation and ODN Delivery In Vivo
Domestic crossbred pigs (Sus scrofa) weighing from 23 to 31 kg were premedicated with aspirin (650 mg PO) before the study. General anesthesia consisted of an intramuscular injection of ketamine (20 mg/kg) and xylazine (4 mg/kg). Additional doses of anesthesia were given intravenously throughout the experiment. The right external carotid artery was surgically exposed, and heparin (10 000 U) was administered intravenously. Using an 8F SAL 1 guiding catheter (Medtronic Interventional Vascular, Inc), the coronary ostia were cannulated under fluoroscopic guidance, and intracoronary nitroglycerin was administered (100 pg). Afterward, selected segments of coronary arteries were denuded using an oversized balloon (3.5 to 4.0 mm), which was inflated three times (6 to 10 atm) for 30 seconds. This procedure results in the induction of neointimal lesions containing predominantly VSMCs.15,16 Animals were randomized to the control group (n= 12) receiving either vehicle injection (saline, n=3) or sense ODNs (n=9, 1 mg per vessel) or the treated group receiving c-myc antisense ODNs (n=13, 1 mg per vessel). The oversized balloon was replaced with a porous balloon (3.0 to 3.5 mm, kindly provided by USCI, Inc), which was advanced to the site of coronary denudation. All intramural injections were carried out under 4 atm of pressure within 5 minutes of denuding injury. The total volume of injectate administered via a porous balloon was 2 mL per vessel. Then, final coronary angiograms were recorded to confirm the continued vessel patency. The catheters were removed, surgical wounds were repaired, and the animals were allowed to recover. At the indicated times, the animals were given a lethal dose of sodium pentobarbital (100 mg/kg IV).
Biodistribution of ODNs In Vivo
15-Mer ODNs were labeled with 35S at each internucleotide linkage and mixed with unlabeled ODNs to achieve a desired concentration (1 mg per vessel, 3.8 uCi). Single transcatheter delivery into denuded coronary arteries was carried out as described above. Afterward, blood samples, injured and noninjured coronary vessels, and peripheral organs remote from the site of injection were collected at various time points as indicated in the text. Tissue samples were rapidly frozen in liquid nitrogen, crushed into fine powder, and then homogenized in lysis buffer (25 mmol/L triphosphate [pH 7.8], 2 mmol/L DTT, 1,2-diaminocyclohexane-N,N,N',N'-tetra-acetic acid, 10% glycerol, 1% Triton X-100, and 50 gg/mL proteinase K). The radioactivity of each sample was counted in a scintillation counter (Pharmacia LKB Biotechnology), and the ODN concentration was quantified according to a standard prepared with a known quantity of 35S-labeled ODNs.
Morphometric Analyses
The heart was rapidly removed and perfused antegradely with 10% buffered formalin for 15 hours. Based on previously recorded coronary angiograms, injured portions of each coronary artery were identified and removed. After dehydration in graded ethanol, the samples were embedded in paraffin and cross sectioned. Serial 5-,um-thick sections at 2-mm increments were stained with Verhoeff-van Gieson stain. The most severe luminal narrowing in denuded segments was identified based on the review of 10 sections per vessel. Morphometric analyses were performed on the sections demonstrating the most severe luminal narrowing as described previously. 
Results

Inhibition of Growth and Type I Collagen Synthesis
To determine potential usefulness of c-myc antisense ODNs in the prevention of neointimal formation, VSMC growth and type I collagen synthesis were evaluated following antisense ODNs in porcine VSMCs before in vivo studies. C-myc antisense ODNs produced a significant growth-inhibitory effect, whereas sense, mismatched, or scrambled ODNs exerted no effect on cell proliferation (Fig 1) The intramural concentrations of ODNs were determined in coronary arteries after transcatheter administration (1 mg). As can be seen in Table 2 , they were 23.4 ,ug/g at 30 minutes, 18.2 ,ug/g at day 1, and 51.0 ,ug/g at day 3, whereas in remote (ie, noninjured) vessels the amount was within the background level. Therefore, local injection using a transcatheter approach produced sustained levels of ODNs in coronary arteries for at least 3 days despite rapid ODN clearance from plasma. The ODN distribution in peripheral organs indicated transient accumulation of ODNs in the kidney and liver (Table 2) . However, the ODN concentration was 2-to 69-fold and 4-to 73-fold higher at the site of injection than levels found in remote organs at 30 minutes and at 24 Fig  4) . Likewise, the maximal neointimal thickness was 0.48±0.09 mm in the control group, whereas in the c-myc antisense-treated group it was 0.20±0.04 mm (P<.01, Fig 4) . Thus, a single transcatheter administration of c-myc antisense ODNs produced 70% and 58% reductions in neointimal area and thickness, respectively. These changes resulted in the improvement in residual coronary lumen from 64±6% in the control group to 81±5% in the antisense-treated group (P<.05). Because neointimal formation is related to the severity of medial injury, we have compared histological injury score (Table 3) between the control and the antisense-treated groups. Mean injury score was 2.7±0.4 in the control group and 2.0±0.3 in the antisense-treated group (P=NS). This demonstrated comparable vascular injury, indicating that the observed reduction in neointimal formation could not be attributed to differences in the severity of denudation. When the maximal neointimal area was further analyzed as a continuous function of histological injury, c-myc antisense oligomers reduced neointimal formation even in those vessels with more advanced medial disruption (slopes: P=.001, Fig 5) . Fig 6 illustrates reductions in neointimal formation in porcine coronary arteries following c-myc antisense ODNs compared with the sensetreated animals.
Discussion
The c-myc nuclear proto-oncogene is a ubiquitous phosphoprotein that is believed to regulate gene expression on transcriptional17 and posttranscriptional18 levels resulting in cell proliferation and their dedifferentiation. VSMCs derived from atherosclerotic lesions exhibit increased expression of c-myc, 19 and balloon injury itself provides a powerful stimulus for an increase in c-myc expression.20,21 This study presents the evidence for the inhibition of two different characteristics of VSMCs, ie, growth and synthetic function, in response to c-myc antisense ODNs. These findings were paralleled by a significant reduction in neointimal formation after a single transcatheter administration of c-myc antisense ODNs in a porcine model of coronary arterial denudation. Therefore, the c-myc nuclear proto-oncogene appears to have an important role contributing to neointimal formation.
Synthetic Phenotype of VSMCs in the Process of Vascular Restenosis
VSMCs are responsible for a broad spectrum of functions including maintaining vascular tone as well as the repair and remodeling of the vessel wall. To accomplish such multiple tasks, VSMCs ODNs lost into the circulation were rapidly cleared from the plasma, transiently accumulating in the liver and kidney, which is consistent with previous studies examining the biodistribution of ODNs.42-44 Of note, ODN concentration was increased in the coronary arterial wall 3 days after transcatheter administration. This may be due to differences in ODN delivery, which depends on the conditions of intramural injection (eg, balloon-to-artery ratio). However, redistribution of ODNs from repository organs to denuded vessels cannot be entirely excluded since ODN concentrations in the liver and kidney were declining at the same time. Additional studies are necessary to determine the exact localization of ODNs in the denuded coronary arterial wall as well as their intactness.
Study Limitations and Future Directions
Our results suggest that the reduction in neointimal formation in nonatherosclerotic coronary a 
